DEERFIELD MANAGEMENT COMPANY, L.P. 组合持仓
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001009258
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
Q4 2023 · 219 持仓数 · 申报总市值 $4.98B · 前十大集中度 60.5% · 更新于 2026-10-18
最后更新: 2026-10-18 · 来源: SEC EDGAR Form 13F-HR
换手率: 35.8% · 5 新建 · 12 减仓 · 12 清仓
主动份额(对标 S&P 500): 99.7% · 对比 QQQ: 100.0% — 组合中区别于指数权重的部分(越高越主动) · 排名
估算季度收益 (Q2 2026 → Q3 2026): -8.8% · 对比 SPY -10.9% · 上季市值 $7.98B — 按上季持仓市值以本季涨跌加权估算 · 排名
估算季内收益 (Q3 2026 → 最新收盘): +1.0% · 对比 SPY -1.2% · 最新申报市值 $4.99B — 最新申报持仓按季内至今涨跌加权(仍在变动) · 排名
在 Q4 2023 的 13F 申报中,DEERFIELD MANAGEMENT COMPANY, L.P. 披露了 219 个股票持仓,合计申报市值 $4.98B。前十大持仓占申报市值的 60.5%,组合属于集中型。HoldingsHub 将其风格标签归纳为 Mid / Focused / Health Tilt / High Turnover。
截至 Q4 2023,最大的披露持仓包括 NUVL($1.47B)、GKOS($414.91M)、VTRS($215.12M)。行业分布上,占比最高的板块为 医疗保健 54.0%, 工业 1.1%。较上一季度,板块上主要增配 Other(+5.7 个百分点),同时减配 Information Technology(-0.7 个百分点)、Industrials(-1.9 个百分点)。
与上一季度相比,DEERFIELD MANAGEMENT COMPANY, L.P. 新建 5 个仓位、减持 12 个、清仓 12 个,换手率约 35.8%。持仓组合与上季度的重合率约为 28%。
Q4 2023 最大新建仓位为 OSCR($102.91M)、BAX($52.53M)、EMBC($26.22M)。
较上季度清仓的 12 个仓位中,金额最大的是 NTIC($53.00M)、ICPT($38.52M)、HCAT($28.52M)。
以上数据来自该基金的 SEC 13F 申报。13F 需在季度结束后 45 天内提交,仅涵盖 10 万美元以上的多头持仓,不含空头与非 13F 资产类别,因此本页反映的是季末快照,并非基金的实时持仓。
新建仓(Q4 2023)
- OSCR OSCAR HEALTH INC · $102.91M
- BAX BAXTER INTL INC · $52.53M
- EMBC EMBECTA CORP · $26.22M
- LKFT LAKEFRONT BIOTHERAPEUTICS NV · $25.29M
- PHVS PHARVARIS N V · $22.78M
- NKTX NKARTA INC · $22.44M
- PRLD PRELUDE THERAPEUTICS INC · $17.65M
- REPL REPLIMUNE GROUP INC · $15.27M
完全清仓(较上季)
- NTIC NORTHERN TECHNOLOGIES INTL C · 上季市值: $53.00M
- ICPT INTERCEPT PHARMACEUTICALS IN · 上季市值: $38.52M
- HCAT HEALTH CATALYST INC · 上季市值: $28.52M
- ROIV ROIVANT SCIENCES LTD · 上季市值: $18.74M
- PTCT PTC THERAPEUTICS INC · 上季市值: $17.51M
- CRBU CARIBOU BIOSCIENCES INC · 上季市值: $16.73M
- TARS TARSUS PHARMACEUTICALS INC · 上季市值: $13.40M
- DNLI DENALI THERAPEUTICS INC · 上季市值: $12.27M
内部人交易(Form 4)
DEERFIELD MANAGEMENT COMPANY, L.P. 最新申报的 SEC Form 4 买卖——当该基金对某只股票的持股超过 10% 后,交易须在两个交易日内申报。
| 交易日期 | 交易方向 | 证券 | 股数 | 价格 | 申报 |
|---|---|---|---|---|---|
| 2026-07-15 | D | Nuvalent, Inc. | 3,444 | $124.00 | SEC 原文 |
| 2026-07-15 | U | Nuvalent, Inc. | 5,146 | $124.00 | SEC 原文 |
| 2026-07-15 | D | Nuvalent, Inc. | 650,000 | $124.00 | SEC 原文 |
| 2026-07-15 | D | Nuvalent, Inc. | 8,299,225 | $124.00 | SEC 原文 |
| 2026-06-16 | 授予 | Nuvalent, Inc. | 3,444 | — | SEC 原文 |
| 2026-06-11 | 转换 | Parabilis Medicines, Inc. | 407,132 | — | SEC 原文 |
| 2026-06-11 | 转换 | Parabilis Medicines, Inc. | 260,992 | — | SEC 原文 |
| 2026-06-11 | 转换 | Parabilis Medicines, Inc. | 149,238 | — | SEC 原文 |
基金介绍
DEERFIELD MANAGEMENT COMPANY, L.P.是一家位于纽约的对冲基金,由Marianne和James Chadwin创立,以其结合量化和基本面研究的方法而闻名,主要专注于医疗保健和生物技术投资。
投资方法
结合量化和基本面分析
专注于医疗保健和生物技术领域
利用公开和私人投资策略
资产类别与策略
主要专注于多头/空头股票头寸
专门从事医疗保健和生物技术投资
也投资于具有强大基本面研究的其他领域
关键人员
Marianne Chadwin(联合创始人)
James Chadwin(联合创始人)
经验丰富的投资组合经理和研究团队
资产规模与表现
管理约191亿美元的资产
表现数据未公开披露
所有信息均基于公开的SEC文件和公司披露。
| # | 公司 | 股数 | 金额 | 权重 | Allocation | 变化 |
|---|---|---|---|---|---|---|
| 1 |
|
19.99M | $1.47B | 29.53% | 持有 | |
| 2 |
|
271.45M | $414.91M | 8.33% | 持有 | |
| 3 |
|
19.86M | $215.12M | 4.32% | 持有 | |
| 4 |
|
101.04M | $172.44M | 3.46% | 持有 | |
| 5 |
|
8.89M | $149.42M | 3.00% | 增持 | |
| 6 |
|
1.99M | $147.81M | 2.97% | 持有 | |
| 7 |
|
116.95M | $123.49M | 2.48% | 增持 | |
| 8 |
|
896.72K | $118.15M | 2.37% | 减持 | |
| 9 |
|
11.25M | $102.91M | 2.07% | 新进 | |
| 10 |
|
5.23M | $100.78M | 2.02% | 减持 | |
| 11 |
|
13.61M | $99.20M | 1.99% | 持有 | |
| 12 |
|
2.58M | $94.33M | 1.89% | 增持 | |
| 13 |
|
2.63M | $93.59M | 1.88% | 增持 | |
| 14 |
|
5.79M | $93.36M | 1.87% | 减持 | |
| 15 |
|
3.09M | $88.62M | 1.78% | 增持 | |
| 16 |
|
14.79M | $86.10M | 1.73% | 增持 | |
| 17 |
|
3.02M | $83.05M | 1.67% | 减持 | |
| 18 |
|
16.94M | $77.08M | 1.55% | 持有 | |
| 19 |
|
5.31M | $76.40M | 1.53% | 增持 | |
| 20 |
|
2.11M | $67.36M | 1.35% | 增持 | |
| 21 |
|
4.00M | $64.27M | 1.29% | 持有 | |
| 22 |
|
1.01M | $62.55M | 1.26% | 减持 | |
| 23 |
|
6.40M | $61.51M | 1.24% | 增持 | |
| 24 |
|
11.08M | $60.71M | 1.22% | 持有 | |
| 25 |
|
1.36M | $52.53M | 1.05% | 新进 | |
| 26 |
|
5.00M | $51.73M | 1.04% | 持有 | |
| 27 |
|
1.13M | $49.17M | 0.99% | 持有 | |
| 28 |
|
151.57K | $48.94M | 0.98% | 减持 | |
| 29 |
|
2.01M | $45.58M | 0.92% | 减持 | |
| 30 |
|
3.93M | $43.03M | 0.86% | 持有 | |
| 31 |
|
178.92K | $38.82M | 0.78% | 增持 | |
| 32 |
|
822.81K | $33.54M | 0.67% | 增持 | |
| 33 |
|
3.49M | $30.04M | 0.60% | 增持 | |
| 34 |
|
5.32M | $29.74M | 0.60% | 增持 | |
| 35 |
|
4.54M | $27.19M | 0.55% | 增持 | |
| 36 |
|
464.29K | $26.82M | 0.54% | 增持 | |
| 37 |
|
1.38M | $26.22M | 0.53% | 新进 | |
| 38 |
|
1.76M | $25.71M | 0.52% | 增持 | |
| 39 |
|
348.00K | $25.65M | 0.52% | 增持 | |
| 40 |
|
622.11K | $25.29M | 0.51% | 新进 | |
| 41 |
|
1.28M | $23.80M | 0.48% | 持有 | |
| 42 |
|
812.24K | $22.78M | 0.46% | 新进 | |
| 43 |
|
3.40M | $22.44M | 0.45% | 新进 | |
| 44 |
|
791.74K | $21.42M | 0.43% | 减持 | |
| 45 |
|
965.43K | $20.83M | 0.42% | 增持 | |
| 46 |
|
4.13M | $17.65M | 0.35% | 新进 | |
| 47 |
|
1.81M | $15.27M | 0.31% | 新进 | |
| 48 |
|
1.54M | $15.25M | 0.31% | 增持 | |
| 49 |
|
1.54M | $12.52M | 0.25% | 持有 | |
| 50 |
|
1.07M | $8.52M | 0.17% | 增持 | |
常见问题
What did DEERFIELD MANAGEMENT COMPANY, L.P. buy in 2023-Q4?
In its 2023-Q4 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. reported 219 equity positions worth $4.98B in aggregate; its largest disclosed positions were NUVL ($1.47B), GKOS ($414.91M), VTRS ($215.12M).
How large is DEERFIELD MANAGEMENT COMPANY, L.P.'s portfolio?
DEERFIELD MANAGEMENT COMPANY, L.P. reported $4.98B of long equity holdings across 219 positions as of 2023-Q4. Top-10 holdings account for 60.5% of reported value.
What is DEERFIELD MANAGEMENT COMPANY, L.P.'s investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.